Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Virally Suppressed People With HIV
2024-513714-36-01Phase 2Authorised
- Sponsor
- Germans Trias i Pujol Research Institute
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dasatinib in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Germans Trias i Pujol Research Institute. Primary endpoints: Grade 3/4 treatment-related adverse events or laboratory abnormalities and SAMHD1 phosphorylation in CD4+ T cells. Planned start Jun 2024; status: authorised.
02
Drugs
dasatinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-513714-36-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513714-36-01.